platoseedplatoseed
One-time, device-based treatment for heart failure
Heart failure impacts millions worldwide and is associated with poor quality of life and high mortality rates. Because the heart cannot pump efficiently, fluids buildup around the body. Fluid overload is the main driver behind patient symptoms (shortness of breath, fatigue, chest pain, etc.) and hospitalizations. Our minimally invasive device leverages the body's innate fluid management system to offload trapped fluid and prevent subsequent rounds of buildup. The one-time procedure has sustained effect -- keeping patients healthier, happier, and out of the hospital.
Founder & CEO of Selera Medical, developing paradigm-shifting technology for heart failure patient management. Previous experience includes Innovation Fellow at Stanford Biodesign, CoS running internal operations at a healthtech startup, R&D engineer developing cardiovascular devices at Medtronic. Masters in biomedical engineering and engineering management from Duke.
Kevin is co-founder and CTO of Selera Medical, a medical device startup developing a minimally invasive therapy for congestive heart failure. Prior to this, he was an Innovation Fellow in the Stanford Byers Center for Biodesign. Kevin received his undergraduate bioengineering degree from Stanford and his PhD in bioengineering from the University of Pennsylvania, where he conducted research at the intersection of robotics, stroke rehabilitation, and cognitive neuroscience.
Device-based approach to better heart failure patient care
Selera develops a one-time, minimally invasive procedure (MILO) to offload the lymphatic system and remove excess fluid in heart failure patients, aiming to reduce symptoms and hospitalizations from fluid overload. The company seeks collaboration with cardiologists and interventional radiologists for product testing and clinical trials.
From the original launch (Feb 2024) — may be outdated.
Catheter-based solution to treat chronic heart failure.
Predicting and preventing heart disease.
